{"id":60487,"date":"2024-02-28T06:51:06","date_gmt":"2024-02-28T06:51:06","guid":{"rendered":"https:\/\/medsname.com\/rofaday\/"},"modified":"2026-04-30T10:23:46","modified_gmt":"2026-04-30T10:23:46","slug":"rofaday","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/rofaday\/","title":{"rendered":"Rofaday"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 28px 0;border-radius:4px;\">\n<h3 style=\"margin:0 0 10px 0;font-size:18px;color:#1a1a1a;\">\u26a1 Quick Answer \u2014 What is Rofaday?<\/h3>\n<p><strong>Rofaday<\/strong> indeholder <strong>roflumilast 500 mcg<\/strong>, en <strong>oral selective phosphodiesterase-4 (PDE4) inhibitor<\/strong> taken once daily for <strong>severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis phenotype and frequent exacerbations<\/strong>. Roflumilast is anti-inflammatory rather than bronchodilator \u2014 it suppresses neutrophil and macrophage activation in airways, reducing exacerbation frequency by ~17% in landmark trials (M2-124, M2-125, REACT). It is added on top of optimal LAMA + LABA (\u00b1 ICS) in patients with severe disease. Manufactured by <strong>Cipla<\/strong>.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Hvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede <a href=\"https:\/\/medsbase.com\/da\/reviews\/\">kundeanmeldelser<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Hver ordre er d\u00e6kket af vores <a href=\"https:\/\/medsbase.com\/da\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n<div style=\"background:#f4f8fb;border:1px solid #e0e0e0;padding:12px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;text-align:center;\">\n<strong>\ud83d\udd12 Krypteret betaling<\/strong> \u00b7 <strong>\ud83d\udcb3 Verificeret betalingsprocessor<\/strong> \u00b7 <strong>\ud83d\ude9a Verdensomsp\u00e6ndende forsendelse<\/strong> \u00b7 <strong>\u2b50 4,9\/5 fra 1.400+ kunder<\/strong>\n<\/div>\n<h2>What Is Rofaday?<\/h2>\n<p>Rofaday is an oral PDE4 inhibitor for severe COPD. Roflumilast is the only PDE4 inhibitor licensed for COPD \u2014 sold internationally as Daxas (AstraZeneca) and Daliresp. It is a niche but well-evidenced add-on for the chronic bronchitis phenotype.<\/p>\n<h2>How Does Rofaday Work?<\/h2>\n<p>Phosphodiesterase-4 (PDE4) is the dominant cyclic AMP-degrading enzyme in inflammatory cells (neutrophils, macrophages, eosinophils, T-cells). Inhibiting PDE4 raises cyclic AMP in these cells, suppressing:<\/p>\n<ul>\n<li>Neutrophil chemotaxis and degranulation in airways<\/li>\n<li>Macrophage cytokine release (TNF-\u03b1, IL-8)<\/li>\n<li>Airway smooth-muscle proliferation and fibroblast activation<\/li>\n<li>Mucus hypersecretion and goblet-cell hyperplasia<\/li>\n<\/ul>\n<p>The clinical result is a 15\u201317% reduction in COPD exacerbation rate when added to optimal inhaled therapy.<\/p>\n<h2>\u2014 det forst\u00e6rker den normale fysiologiske respons snarere end at udl\u00f8se en kunstigt.<\/h2>\n<ul>\n<li><strong>Severe COPD (FEV1 &lt;50% predicted) with chronic bronchitis<\/strong> and a history of exacerbations, on top of optimal LAMA + LABA (\u00b1 ICS)<\/li>\n<li><strong>Frequent exacerbator phenotype<\/strong> with persistent productive cough<\/li>\n<\/ul>\n<h2>Rofaday Dosage<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Patient<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Dosis<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Hyppighed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Adults \u2014 start<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>250 mcg<\/strong> for first 4 weeks<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">En gang dagligt<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Voksne \u2014 vedligeholdelse<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><strong>500 mcg<\/strong><\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Once daily, with or without food<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Leversvigt<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid (Child-Pugh B\/C)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Side Effects of Rofaday<\/h2>\n<ul>\n<li><strong>V\u00e6gttab<\/strong> (averages 2\u20133 kg in trials \u2014 monitor; reverse if &gt;5%)<\/li>\n<li>Diarrhoea, nausea (commonest reason for discontinuation; usually settles after first 2\u20134 weeks)<\/li>\n<li>Hovedpine<\/li>\n<li>S\u00f8vnl\u00f8shed, angst<\/li>\n<li>Dyspepsia, abdominal pain<\/li>\n<li>Mood changes \u2014 depression, anxiety; rarely suicidal ideation (warning)<\/li>\n<\/ul>\n<p><strong>Alvorligt \u2014 stop og s\u00f8g hj\u00e6lp:<\/strong><\/p>\n<ul>\n<li>Severe weight loss (&gt;5% body weight)<\/li>\n<li>New or worsening depression, suicidal thoughts<\/li>\n<li>Severe persistent diarrhoea<\/li>\n<li>Alvorlig allergisk reaktion<\/li>\n<\/ul>\n<h2>Advarsler og forholdsregler<\/h2>\n<ul>\n<li><strong>Mood and behaviour:<\/strong> screen for depression before starting; warn patients\/families to report new mood symptoms.<\/li>\n<li><strong>Weight loss:<\/strong> baseline and 3-monthly weight monitoring; if loss exceeds 5%, review or stop.<\/li>\n<li><strong>Nedsat leverfunktion:<\/strong> avoid in Child-Pugh B and C.<\/li>\n<li><strong>4-week dose titration<\/strong> (250 mcg) reduces GI side effects and diarrhoea \u2014 most patients can then tolerate 500 mcg.<\/li>\n<li><strong>Not a bronchodilator<\/strong> \u2014 does not replace LAMA, LABA, or ICS.<\/li>\n<li><strong>Graviditet og amning:<\/strong> kontraindikeret.<\/li>\n<li><strong>L\u00e6gemiddelinteraktioner:<\/strong> CYP3A4 inducers (rifampicin) reduce levels \u2014 avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels \u2014 caution.<\/li>\n<\/ul>\n<h2>Kontraindikationer<\/h2>\n<ul>\n<li>Hypersensitivity to roflumilast<\/li>\n<li>Moderate-to-severe hepatic impairment (Child-Pugh B\/C)<\/li>\n<li>Graviditet<\/li>\n<\/ul>\n<h2>L\u00e6gemiddelinteraktioner<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Interagerende l\u00e6gemiddel<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Effekt<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Hvad skal der g\u00f8res<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">CYP3A4 inducers (rifampicin, phenobarbital, phenytoin, carbamazepine)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce roflumilast levels by 50%<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Undg\u00e5<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin, enoxacin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raise roflumilast levels \u2014 increase side effect risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Caution; consider lower dose<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Oral contraceptives containing gestodene<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Modest increase in roflumilast levels<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">No dose adjustment usually needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Opbevaring<\/h2>\n<ul>\n<li>Opbevares under <strong>25\u00b0C<\/strong> p\u00e5 et k\u00f8ligt, t\u00f8rt sted v\u00e6k fra direkte sollys.<\/li>\n<li>Opbevar i originalemballage inden brug for at beskytte mod fugt og lys.<\/li>\n<li>Brug ikke efter den udl\u00f8bsdato, der er trykt p\u00e5 strimlen.<\/li>\n<li>Opbevar utilg\u00e6ngeligt for b\u00f8rn.<\/li>\n<\/ul>\n<h2>Relaterede alternativer p\u00e5 MedsBase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/asthalin-inhaler\/\"><strong>Asthalin Inhalator \u2014 salbutamol lindrende<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/budecort-inhaler\/\"><strong>Budecort Inhalator \u2014 budesonide ICS forebyggende<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/foracort-inhaler\/\"><strong>Foracort Inhalator \u2014 budesonide + formoterol ICS-LABA<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/tiova-inhaler\/\"><strong>Tiova Inhalator \u2014 tiotropium LAMA til KOL<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/montair\/\"><strong>Montair \u2014 montelukast LTRA tablet<\/strong><\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">Ofte stillede sp\u00f8rgsm\u00e5l<\/h2>\n<h3>When is Rofaday added?<\/h3>\n<p>For severe COPD (FEV1 <50% predicted) with chronic bronchitis phenotype and a history of frequent exacerbations on top of optimal LAMA + LABA (\u00b1 ICS). Not for mild COPD or asthma.<\/p>\n<h3>Why must I start at 250 mcg?<\/h3>\n<p>A 4-week titration at 250 mcg dramatically reduces GI side effects (diarrhoea, nausea) \u2014 most patients can then move to the maintenance 500 mcg without intolerance.<\/p>\n<h3>How much does Rofaday reduce exacerbations?<\/h3>\n<p>About 15\u201317% reduction in moderate-to-severe COPD exacerbations in landmark trials (M2-124, M2-125, REACT). Most benefit seen in the chronic bronchitis with frequent exacerbator phenotype.<\/p>\n<h3>Will Rofaday make me lose weight?<\/h3>\n<p>Yes \u2014 average 2\u20133 kg in trials. Monitor weight at baseline and every 3 months. If loss exceeds 5%, review indication or stop.<\/p>\n<h3>Hvad med hum\u00f8r\u00e6ndringer?<\/h3>\n<p>Rare but reported. Screen for depression at baseline; counsel patient and family to report new mood symptoms, anxiety, or suicidal thoughts. Stop and review.<\/p>\n<h3>Is Rofaday a bronchodilator?<\/h3>\n<p>No \u2014 it is anti-inflammatory only. Continue your LAMA, LABA, and (where indicated) ICS inhalers.<\/p>\n<h3>Can I take Rofaday during pregnancy?<\/h3>\n<p>Kontraindiceret.<\/p>\n<h3>How does Rofaday compare to triple therapy?<\/h3>\n<p>Triple inhaler (Triohale) and Rofaday tackle COPD exacerbations through different mechanisms (bronchodilation + inflammation suppression vs PDE4-mediated anti-inflammation). Some patients benefit from both.<\/p>\n<h3>What are the most important drug interactions?<\/h3>\n<p>Rifampicin (and other CYP3A4 inducers) reduce Rofaday levels by half \u2014 avoid. Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) raise levels \u2014 caution.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:24px 0;border-radius:4px;font-size:13px;\"><strong>Medicinsk ansvarsfraskrivelse:<\/strong> Denne side er uddannelsesm\u00e6ssig og erstatter ikke professionel medicinsk r\u00e5dgivning. Konsulter altid en kvalificeret sundhedsfaglig person, f\u00f8r du starter, stopper eller \u00e6ndrer enhver inhalator eller respirationsmedicin, is\u00e6r hvis du har andre medicinske tilstande, tager andre receptpligtige l\u00e6gemidler, er gravid eller ammer, eller er over 65 \u00e5r.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterede alternativer<\/h3>\n<p>Andre produkter inden for <strong>Kroniske tilstande<\/strong> som kunder ogs\u00e5 ser:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/glycomet-gp\/\">Glycomet-GP<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/loratin\/\">Loratin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/lasix\/\">Lasix<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/decdan\/\">Decdan<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/hydrocl\/\">Hydrocl<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Reduces lung inflammation<br \/>\n\u2705 Forbedrer lungefunktion<br \/>\n\u2705 Treats chronic bronchitis<br \/>\n\u2705 Decreases COPD exacerbations<br \/>\n\u2705 Enhances breathing capacity<\/p>\n<p>Rofaday contains Roflumilast.<\/p>","protected":false},"featured_media":60488,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3681,3141,3223],"product_tag":[4868,4869],"class_list":{"0":"post-60487","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-asthma-copd-treatment","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_tag-rofaday","10":"product_tag-roflumilast","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product\/60487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/comments?post=60487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media\/60488"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media?parent=60487"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_brand?post=60487"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat?post=60487"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_tag?post=60487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}